發(fā)布時(shí)間：2018-09-18 15:54

【摘要】：目的:通過對比研究單用肝水解肽與肝水解肽聯(lián)合丹參川穹嗪對治療青海地區(qū)肝硬化患者的療效,明確二者有無統(tǒng)計(jì)學(xué)意義,從而更好地指導(dǎo)臨床用藥。方法:從2014年5月-2016年2月青海大學(xué)附屬醫(yī)院肝膽胰科確診并住院治療的肝硬化病人中選取30例作為A組,記錄其性別、年齡、族別及肝功能(Child-Pugh)分級等指標(biāo),作為配對條件。選取符合納入標(biāo)準(zhǔn)、排除標(biāo)準(zhǔn)以及滿足配對條件的肝硬化病人30例作為B組,確保能與A組30例嚴(yán)格配對。A組單用肝水解肽100mg,靜滴,1次/日,進(jìn)行治療,B組應(yīng)用肝水解肽100mg加丹參川穹嗪10ml,靜滴,1次/日進(jìn)行治療。分別觀察并記錄治療前、治療10天、治療20天后兩組所有肝硬化患者的肝功能生化指標(biāo)。用SPSS 17.0錄入數(shù)據(jù)并進(jìn)行統(tǒng)計(jì)學(xué)分析,由于該樣本量較小(30對),配對樣本差值經(jīng)正態(tài)性檢驗(yàn),不服從正態(tài)分布,呈偏態(tài)分布,故該資料用中位數(shù),四分位數(shù)間距即M,(QL-QU)表示,組間比較用秩和檢驗(yàn),以a=0.05為顯著性檢驗(yàn)水準(zhǔn)。結(jié)果:治療10天時(shí),經(jīng)秩和檢驗(yàn)五項(xiàng)指標(biāo)比較得出的Z值分別為:ALT,1.214;AST,0.508;ALP,1.080;GGT,0.463;CHE,1.512;P值分別為:ALT,0.225;AST,0.611;ALT,0.280;GGT,0.644;CHE,0.131。每項(xiàng)指標(biāo)P0.05。治療20天時(shí),經(jīng)秩和檢驗(yàn)五項(xiàng)指標(biāo)比較得出的Z值分別為:ALT,-2.220;AST,-0.035;ALP,-2.494;GGT,-2.403;CHE,-2.464;P值分別為:ALT,0.026;AST,0.738;ALT,0.013;GGT,0.016;CHE,0.008。其中,ALT、ALP、GGT、CHE指標(biāo)P0.05,AST指標(biāo)P0.05。結(jié)論:通過單用肝水解肽與肝水解肽聯(lián)合丹參川穹嗪對治療青海地區(qū)60例肝硬化患者的療效對比分析,在治療10天時(shí),兩組所觀察指標(biāo)無明顯差異,結(jié)果無統(tǒng)計(jì)學(xué)意義;在治療20天時(shí),兩組所觀察的五項(xiàng)指標(biāo)中有四項(xiàng)有明顯差異,結(jié)果有統(tǒng)計(jì)學(xué)意義,僅AST一項(xiàng)未見明顯差異,結(jié)果無統(tǒng)計(jì)學(xué)意義。
[Abstract]:Objective: to compare the efficacy of liver hydrolysate peptide and Danshen daizizine in the treatment of liver cirrhosis in Qinghai area, and to find out whether there is statistical significance between them. Methods: from May 2014 to February 2016, 30 patients with liver cirrhosis diagnosed and hospitalized in Department of Hepatobiliary Pancreatology, affiliated Hospital of Qinghai University were selected as group A, and their sex, age, ethnicity and Child-Pugh grading were recorded as matched conditions. Thirty cirrhotic patients who met the inclusion criteria, exclusion criteria and matching conditions were selected as group B to ensure that only 100 mg of hepatic hydrolysate was given intravenously to group A and 30 cases of group A were strictly matched. Group B was treated with liver hydrolysate peptide 100mg and danshen dachonosin 10 ml once a day. The biochemical indexes of liver function were observed and recorded before, 10 days and 20 days after treatment. The data were inputted by SPSS 17.0 and analyzed statistically. Because the sample size was small (30 pairs), the difference value of matched sample was tested by normality, and the data was skewed from normal distribution. Therefore, the data was represented by median, quartile spacing, I. E. M, (QL-QU). The rank sum test was used in the comparison between groups, with a significant test level of 0.05. Results: after 10 days of treatment, the Z values of the five indexes by rank sum test were as follows: 1: ALT 1.214A AST 0.508U ALPU 1.080 GGT0.463CHE1 512P = 0. 225m AST 0.611ALT0.280GGT0.644CHE 0.131. Each index (P0.05). After 20 days of treatment, the Z values compared with the five indexes of rank sum test were as follows: 1 / ALT ~ (-2.220) AST ~ (-0.035) ~ (-2.494) ~ (-2.404) GGT-2.404 ~ (th) Chem -2.464 (P = 0. 026) and 0. 738% ALT ~ (0.013) GGT ~ (0.016) Chem 0.008, respectively. The GGTCHE index P0.05and AST P0.05. Conclusion: there was no significant difference between the two groups in the treatment of 60 patients with liver cirrhosis in Qinghai area after 10 days of treatment, and there was no significant difference between the two groups. After 20 days of treatment, four of the five indexes observed in the two groups were significantly different, the results were statistically significant, only one item of AST had no significant difference, but the results were not statistically significant.
【學(xué)位授予單位】：青海大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2016
【分類號】：R575.2

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 林濤;王優(yōu);林愛俊;;肝水解肽治療抗結(jié)核藥物性肝損害療效觀察[J];臨床肺科雜志;2008年02期

2 王燦;吳利紅;史芳亮;邵泓;陳鋼;;肝水解肽體外活性測定方法的探討研究[J];藥物分析雜志;2011年10期

3 林上炎;王燦;邵泓;陳鋼;;肝水解肽體外生物學(xué)活性測定方法優(yōu)化[J];中國醫(yī)藥工業(yè)雜志;2013年06期

4 李靚;;肝水解肽過敏1例[J];肝臟;2013年11期

5 楊玲;;肝水解肽注射液治療新生兒高膽紅素血癥的療效評價(jià)[J];中國社區(qū)醫(yī)師(醫(yī)學(xué)專業(yè));2012年12期

6 王燦;吳利紅;林上炎;邵泓;陳鋼;;肝水解肽生物學(xué)活性測定方法的應(yīng)用[J];中國藥師;2013年05期

7 賀樹卿;杜娟;;利福平聯(lián)合肝水解肽治療肺結(jié)核療效觀察[J];北方藥學(xué);2013年05期

8 李娜;趙亞松;;肝水解肽注射液致藥物反應(yīng)性高熱三例[J];華北國防醫(yī)藥;2010年05期

9 宋國新;韋志強(qiáng);;肝水的中藥成方治療窺探[J];北方藥學(xué);2013年07期

10 王廣;呂高輝;沈新影;王英偉;;豬源、牛源肝水解肽的質(zhì)量對比研究[J];中國生化藥物雜志;2008年02期

相關(guān)會(huì)議論文 前1條

1 顧生旺;薛國良;蔡濤;厲芹;胡大山;初春;周建標(biāo);;升白蛋白膠囊與肝水解肽治療肝硬化低白蛋白血癥47例[A];第五屆全國肝臟疾病臨床暨中華肝臟病雜志成立十周年學(xué)術(shù)會(huì)議論文匯編[C];2006年

相關(guān)碩士學(xué)位論文 前3條

1 董金超;肝水解肽與肝水解肽聯(lián)合丹參川穹嗪對青海地區(qū)肝硬化患者療效的分析[D];青海大學(xué);2016年

2 周月喬;肝水解肽注射液的制備工藝優(yōu)化及質(zhì)量標(biāo)準(zhǔn)提高研究[D];安徽中醫(yī)藥大學(xué);2013年

3 李慧梅;肝水解肽治療肝硬化腹水的療效觀察[D];吉林大學(xué);2007年

，

本文編號：2248397